Related MeSH Hierarchy (6)
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Protein Disorders » Paraproteinemias » Multiple Myeloma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Plasma Cell » Multiple Myeloma
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Hemostatic Disorders » Multiple Myeloma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hemorrhagic Disorders » Hemostatic Disorders » Multiple Myeloma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Multiple Myeloma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Paraproteinemias » Multiple Myeloma
Description
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. MeSH
Hierarchy View
Subtype Terms (1)
Leukemia, Plasma Cell
46 drugs (35 approved, 11 experimental)
Approved Indicated Drugs (28)
Phase 3 Indicated Drugs (97)
acetylsalicylic acid (aspirin)
autologous hematopoietic stem cells
autologous mesenchymal stem cells
bone marrow derived mesenchymal stem cells
Phase 2 Indicated Drugs (246)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
90Yttrium-labelled Anti-CD66 Monoclonal Antibody
activated marrow infiltrating lymphocytes
allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
allogeneic natural killer cells
autologous dendritic cells electroporated with wt1 mrna
autologous epstein-barr virus-specific cytotoxic t lymphocytes
autologous ex-vivo expanded effector cells
autologous natural killer cells
dendritic cell tumor fusion vaccine
human fecal microbiota (Reybota)
ibritumomab tiuxetan (Zevalin)
immune globulin (human) (Gamastan)
monosialotetrahexosyl ganglioside
muromonab cd3 (Orthoclone OKT3)
Phase 1 Indicated Drugs (285)
anti-ley-scfv-cd28-zeta vector
autologous immunoglobulin idiotype-klh conjugate vaccine
autologous muc1-activated t-cells
cd34-tk75 transduced donor lymphocytes
ct7, mage-a3, and wt1 mrna-electroporated langerhans cells
deeptag-gprc5d targeted car t-cells
donor memory t cells that have been depleted of cd62l+
kir-ligand mismatched haplo-identical natural killer cells
krn7000 loaded dendritic cells
Other Experimental Indicated Drugs (38)
Organization Involved with Phase 3 Indications (251)
Assistance Publique - Hôpitaux de Paris
Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
Blood and Marrow Transplant Clinical Trials Network
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Central European Myeloma Study Group
Central Hospital of Kanta-Hame
Centre hospitalier de Mulhouse
Changshu First People's Hospital
City of Hope National Medical Center
Clinica Universidad de Navarra
Complejo Hospitalario de Salamanca
Deutsche Studiengruppe Multiples Myelom
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Group for Blood and Marrow Transplantation
European Organisation for Research and Treatment of Cancer
Federal University of Rio de Janeiro
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Grupo Cooperativo de Hemopatías Malignas
Grupo de Estudos Multicentricos em Onco-Hematologia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano per lo Studio del Mieloma Multiplo
Hoosier Cancer Research Network
Hospital Doce de Octubre Madrid
Hospital Universitari Son Dureta
HOVON - Dutch Haemato-Oncology Association
Huai'an Second People's Hospital
Icahn School of Medicine at Mount Sinai
Intergroupe Francophone du Myelome
International Myeloma Foundation (IMF)
Maria Sklodowska Curie Children's Hospital
Myeloma Institute for Research & Therapy
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Norwegian University of Science and Technology
Oregon Health and Science University
Prologue Research International
Royal Marsden Hospital NHS Trust
Russian Academy of Medical Sciences
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Simcere Pharmaceutical Co., Ltd
State University of New York, Brooklyn
State University of New York, Buffalo
The University of Texas, Dallas
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University Hospital of North Norway
University of Alabama, Birmingham
University of California, Davis
Organization Involved with Phase 2 Indications (340)
Academic and Community Cancer Research United
Alexandra Hospital, Athens, Greece
American Society of Clinical Oncology
Apogee Biotechnology Corporation
Arbeitsgemeinschaft medikamentoese Tumortherapie
Azienda Ospedaliera di Bolzano
Azienda Ospedaliera Universitaria Senese
Big Ten Cancer Research Consortium
British Columbia Cancer Agency
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Centre de Commercialisation en Immunothérapie du Cancer
Centre de Commercialisation en Immunothérapie du Cancer (C3i)
Centre Hospitalier de Blois -BLOIS
China Food and Drug Administration
Chongqing Precision Biotech Co., Ltd
Christian Medical College, Vellore, India
Ciusss de L'Est de l'Île de Montréal
Gleneagles Hospital, Singapore
Gruppo Italiano Studio Linfomi
Hackensack University Medical Center
Heidelberg Clinical Research Centre
Hellenic Society of Hematology
Herbert Irving Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
HOANNJ-Carol G. Simon Cancer Center
Hospital Universitario Reina Sofía
Huazhong University of Science and Technology
Institut de Cancerologie de l'Ouest Paul Papin
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
International Myeloma Foundation
Isala Clinics, Zwolle, The Netherlands
James Graham Brown Cancer Center
Katholieke Universiteit Leuven
Korean Multiple Myeloma Working Party
Ludwig Institute for Cancer Research
Mater Misericordiae University Hospital
Medical Prognosis Institute A/S
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Myeloma Canada Research Network
Nanyang Technological University
National Health Service, United Kingdom
National Institutes of Health (NIH)
Nij Smellinghe Hospital Drachten
Our Lady of Mercy Medical Center
Pavlov First Saint Petersburg State Medical University
Shanghai Asclepius Meditec Inc.
Shenzhen Geno-Immune Medical Institute
Smerud Medical Research Denmark
Sparrow Regional Cancer Center
Swiss Group for Clinical Cancer Research
TaiGen Biotechnology Co., Ltd.
Taipei Veteran General hospital
The Australasian Leukaemia & Lymphoma Group (ALLG)
The Beijing Pregene Science and Technology Company, Ltd.
The Leukemia and Lymphoma Society
The Wayne D. Kuni and Joan E. Kuni Foundation
Triphase Research and Development Corporation
University of Applied Sciences Würzburg-Schweinfurt
University of British Columbia
University of California, Berkeley
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Maryland, Baltimore County
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (124)
Allife Medical Science and Technology Co., Ltd.
Beijing Immunochina Medical Science & Technology Co., Ltd.
California Institute for Regenerative Medicine (CIRM)
CLL Global Research Foundation
Damon Runyon Cancer Research Foundation
Department of Health and Human Services
Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Hebei Senlang Biotechnology Inc., Ltd.
Henan University of Traditional Chinese Medicine
Infinity Pharmaceuticals, Inc.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
La Jolla Pharmaceutical Company
National Comprehensive Cancer Network
National University of Ireland
New Mexico Cancer Care Alliance
Organization Involved with Other Experimental Indications (10)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.